Provided is an anti-interleukin-8 (IL-8) monoclonal antibody 6G4.2.5. The antibody may be used in diagnostic applications and in the treatment studies of inflammatory disorders.
Figure 1 The anti-IL-8 mAb pair of 5A.12.14 and 6G4.2.5 allows for detection of IL-8 by ELISA.
It indicates that the successful detection of IL-8 using the two different antibodies cannot be attributed to the IL-8 existing in a dimeric state and demonstrates that
6G4.2.5 and A5.12.14 bind to separate epitopes on the IL-8 molecule.
Deforge, L. E., Lowman, H. B., Leong, S. R., Chuntharapai, A., Kim, K. J., & Hébert, C. A. (2000). A neutralizing monoclonal antibody specific for the dimer interface region of IL-8. Cytokine, 12(11), 1620-1629.
Figure 2 A5.12.14 and 6G4.2.5 dose-dependently inhibit IL-8-stimulated release of β-glucuronidase from human neutrophils.
IL-8+A5.12.14, -●-; IL-8+6G4.2.5, -□-; IL-8 alone,◆ ; A5.12.14 alone,△ ; 6G4.2.5 alone, ▼. ID50 (nM): 6G4.2.5, 10.16; A5.12.14, 4.70. Keeping the IL-8 concentration constant at 10 nM, 6G4.2.5 or A5.12.14 was added over a concentration range of 0.65-50 nM and caused a dose-dependent inhibition of β- glucuronidase release.
Deforge, L. E., Lowman, H. B., Leong, S. R., Chuntharapai, A., Kim, K. J., & Hébert, C. A. (2000). A neutralizing monoclonal antibody specific for the dimer interface region of IL-8. Cytokine, 12(11), 1620-1629.
Figure 3 A5.12.14 and 6G4.2.5 detection of wild-type IL-8 and the four monomer variants by ELISA.
A blank (●) was run on each plate in which an equivalent volume of assay diluent was added in place of the mAbs. A: while A5.12.14 bound nearly identically to wild-type IL-8 (-■-) and variant II (--◆--), the binding curve for variant I (- ◯ -) was shifted to the right, and variants III (-▼-) and IV (--△--) were not detected. B: 6G4.2.5 was capable of binding to all of the monomer mutants, although these curves were shifted to the right as compared to wild-type IL-8. The results represent the average of optical density values of duplicate samples. 6G4.2.5 was able to bind to all of the monomer variants in this ELISA format, although the curves were shifted to the right relative to wild-type IL-8.
Deforge, L. E., Lowman, H. B., Leong, S. R., Chuntharapai, A., Kim, K. J., & Hébert, C. A. (2000). A neutralizing monoclonal antibody specific for the dimer interface region of IL-8. Cytokine, 12(11), 1620-1629.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NAB-738-sdAb | Recombinant Anti-human CXCL8 VHH Single Domain Antibody | IHC, ICC, FC, FA, FUNC | Llama VHH |
There are currently no Customer reviews or questions for HPAB-S0084-YC. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.